Company: BIAF
Filing Date: 2025-10-09
Form Type: 424B5
Source: 0001493152-25-017591
Chunk: 8

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-09
Form: 424B5
Chunk 8
---
 common stock             |     | “BIAF”                                                                                                                            |

The number of shares of our common stock that will be outstanding immediately after this offering as shown above is based on 4,498,709 shares outstanding as of October 7, 2025, and excludes:

| ● | 101,448                                                                                                                            
 shares of common stock issuable upon the conversion of                                                                             
 700 shares of Series B Convertible Preferred Stock at an initial conversion price of $6.90                                         
 per share;                                                                                                                         |
| ● | 1,355,273                                                                                                                          
 shares of common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $29.09   
 per share;                                                                                                                         |
| ● | 9,054                                                                                                                              
 shares of common stock issuable upon the exercise of stock options issued under our equity incentive plans with a weighted average 
 exercise price equal to $211.57 per share; and                                                                                     |
| ● | 41,908                                                                                                                             
 shares of our common stock that are reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.           |

| S-3 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves a high degree of risk You should carefully consider the risks described below and all of the information contained or incorporated by reference in this prospectus, including the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2024, any subsequent Quarterly Reports on Form 10-Q, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying base prospectus before deciding whether to purchase the securities offered hereby. Our business, financial condition, results of operations and prospects could be materially and adversely affected by these risks.

Risks Related to This Offering

Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.

Our management will have broad discretion as to the use of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management regarding the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest the net